v3.26.1
Other Financial Statement Information - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 08, 2026
Dec. 31, 2025
Dec. 31, 2024
Concentration Risk [Line Items]              
Impairment of long lived assets       $ 100      
Gross Carrying Amount $ 81,115   $ 81,115     $ 77,416  
Contract with customer, liability 33,293 $ 33,518 33,293 33,518   34,403 $ 33,171
Deferred revenue 23,610   23,610     23,902  
Revenue 151,036 172,908 301,879 327,791      
Recognized foreign currency transaction income (loss) (400) 2,300 (1,100) 3,700      
Change in fair value     (3,466) 0      
Developed technology              
Concentration Risk [Line Items]              
Gross Carrying Amount $ 56,338   $ 56,338     $ 52,639  
Remaining Useful Life in Years 5 years 9 months 18 days   5 years 9 months 18 days        
Proteintech Genomics Inc | Developed technology              
Concentration Risk [Line Items]              
Gross Carrying Amount $ 3,700   $ 3,700        
Remaining Useful Life in Years 10 years   10 years   10 years    
Scale BioScience Inc. Acquisition              
Concentration Risk [Line Items]              
Change in fair value     $ (3,500)        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-07-01              
Concentration Risk [Line Items]              
Expected period of revenue recognition 12 months   12 months        
Products and Services, Excluding Grant Revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-07-01              
Concentration Risk [Line Items]              
Deferred revenue $ 23,600   $ 23,600        
License and royalty revenue              
Concentration Risk [Line Items]              
Revenue $ 1,942 27,751 2,889 44,811      
License and royalty revenue | Takara Bio USA Holdings, Inc.              
Concentration Risk [Line Items]              
Revenue     $ 1,600        
License and royalty revenue | Vizgen, Inc.              
Concentration Risk [Line Items]              
Revenue       16,800      
License and royalty revenue | Bruker Corporation              
Concentration Risk [Line Items]              
Revenue   $ 27,300   $ 27,300